β4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis

Cancer Research

Volumn 65, Issue 23, 2005, Pages 10674-10679

  Bertotti, Andrea ^a   Comoglio, Paolo M ^a   Trusolino, Livio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; EPITHELIUM CELL; FIBROBLAST; GENE FUNCTION; GENE OVEREXPRESSION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTO ONCOGENE; RNA INTERFERENCE; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL STRAIN 3T3; CELL STRAIN COS1; CERCOPITHECUS; GENETICS; HUMAN; IMMUNE DEFICIENCY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; IMMUNOCOMPROMISED HOST; INTEGRIN BETA4; MICE; NIH 3T3 CELLS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 28244478626     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2827     Document Type: Article

References (21)

1. Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signalling. Annu Rev Cell Dev Biol 2003;19:173-206.
2. Hanahan D, Weinberg RA, The hallmarks of cancer. Cell 2000;100:57-70.
3. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996;8:724-30.
4. Falcioni R, Sacchi A, Resau J, Kennel SJ. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue. Cancer Res 1988;48:816-21.
5. 4 integrin. Semin Cancer Biol 2001;11:129-41.
6. 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis. Cancer Res 1993;53:4803-10.
7. 4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643-54.
8. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300.
9. 4 integrin can function independently to promote carcinoma invasion. J Biol Chem 2004;279:32287-93.
10. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50.
11. 4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol 2001;21:5082-93.
12. 4 integrin cytoplasmic domain mediates She signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J Biol Chem 2001;276:1494-502.
13. Shaw LM. Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia 1999;4:367-76.
14. Parr C, Watkins G, Mansel RE, Jang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202-11.
15. 4 integrin and activates RAC and NFkB to mediate anchorage-independent survival of mammary tumors. J Cell Biol 2003;163:1397-407.
16. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-67.
17. 4-integrin gene promoter and enhancers. J Biol Chem 1998;273:33848-55.
18. Gambarotta G, Pistoi S, Giordano S, Comoglio PM, Santoro C. Structure and inducible regulation of the human MET promoter. J Biol Chem 1994;269:12852-57.
19. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
20. Giordano S, Maffe A, Williams TA, et al. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J 2000;14:399-406.
21. 4 genes. Eur J Biochem 1991;199:425-33.